Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 2/2017

01-02-2017 | Original Article

Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera

Published in: Osteoporosis International | Issue 2/2017

Login to get access

Abstract

Summary

In this cross-sectional study of 45 patients with myeloproliferative neoplasms, we found no evidence of secondary osteoporosis.

Introduction

Patients with essential thrombocythemia (ET) and polycythaemia vera (PV) are at increased risk of fractures but the underlying mechanisms have not been settled. We conducted a study to assess bone mineral density, microarchitecture, estimated bone strength and global bone turnover in 45 patients with ET or PV.

Methods

Patients were evaluated in a cross-sectional study with dual energy X-ray absorptiometry (DXA) at the hip and spine; high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal radius and distal tibia; and biochemical markers of bone turnover including pro-collagen type 1 N-terminal pro-peptide, osteocalcin, C-terminal cross-linking telopeptide of type 1 collagen and bone-specific alkaline phosphatase. Also, 45 healthy comparisons, matched on age, height and weight with each patient were included as control subjects.

Results

Patients and comparisons had almost identical BMDs: 0.96 (IQR: 0.85–1.07) g/cm2 and 0.96 g/cm2 (IQR: 0.86–1.05 g/cm2), respectively. As well all microarchitecture and estimated bone strength measures were highly similar in the two groups. Levels of bone turnover markers were within reference values in patients.

Conclusion

These results reveal no evidence of secondary osteoporosis among patients with ET or PV. The mechanism behind the increased fracture risk in ET or PV patients remains unknown.
Literature
1.
Farmer S, Horvath-Puho E, Vestergaard H et al (2013) Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol 163:603–610CrossRefPubMed
2.
Hasselbalch HC (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119:3219–3225CrossRefPubMed
3.
Mesa RA, Niblack J, Wadleigh M et al (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109:68–76CrossRefPubMed
4.
Finazzi G, De Stefano V, Barbui T (2013) Are MPNs vascular diseases? Curr Hematol Malig Rep 8:307–316CrossRefPubMed
5.
Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224–2232CrossRefPubMed
6.
Mesa RA, Scherber RM, Geyer HL (2015) Reducing symptom burden in patients with myeloproliferative neoplasms in the era of JAK inhibitors. Leuk Lymphoma:1–39
7.
Frederiksen H, Farkas DK, Christiansen CF et al (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118:6515–6520CrossRefPubMed
8.
Tefferi A, Guglielmelli P, Larson DR et al (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124:2507–2513 quiz 2615CrossRefPubMedPubMedCentral
9.
Hultcrantz M, Kristinsson SY, Andersson TM et al (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 30:2995–3001CrossRefPubMedPubMedCentral
10.
Hasselbalch HC (2014) Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Rev Hematol 7:203–216CrossRefPubMed
11.
12.
Farmer S, Vestergaard H, Hansen S et al (2015) Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers. Int J Hematol 102:67–75CrossRefPubMed
13.
Oikonomidou PR CC, Yang Z, Crielaard B, Shim JH, Rivella S, Vogiatzi MG. Polycythemia is associated with bone loss and reduced osteoblast activity in mice. Osteoporos Int [Epub ahead of print]
14.
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646–650.
15.
Stone KL, Seeley DG, Lui LY et al (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18:1947–1954CrossRefPubMed
16.
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259CrossRefPubMedPubMedCentral
17.
Cummings SR, Black DM, Nevitt MC, The Study of Osteoporotic Fractures Research Group et al (1993) Bone density at various sites for prediction of hip fractures. Lancet 341:72–75CrossRefPubMed
18.
Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med 2015.
19.
20.
Kanis JA, Melton LJ 3rd, Christiansen C et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141CrossRefPubMed
21.
Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112CrossRefPubMed
22.
Boutroy S, Bouxsein ML, Munoz F, Delmas PD (2005) In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 90:6508–6515CrossRefPubMed
23.
Boutroy S, Van Rietbergen B, Sornay-Rendu E et al (2008) Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women. J Bone Miner Res 23:392–399CrossRefPubMed
24.
Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29:541–549CrossRefPubMed
25.
Swerdlow SHCE, Harris NL et al (2008) WHO Classification of tumours of the Haematopoietic and Lymphoid Tissues. IARC, Lyon, France
26.
Hansen S, Shanbhogue V, Folkestad L et al (2014) Bone microarchitecture and estimated strength in 499 adult Danish women and men: a cross-sectional, population-based high-resolution peripheral quantitative computed tomographic study on peak bone structure. Calcif Tissue Int 94:269–281CrossRefPubMed
27.
Pialat JB, Burghardt AJ, Sode M et al (2012) Visual grading of motion induced image degradation in high resolution peripheral computed tomography: impact of image quality on measures of bone density and micro-architecture. Bone 50:111–118CrossRefPubMed
28.
Burghardt AJ, Kazakia GJ, Ramachandran S et al (2010) Age- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res 25:983–993CrossRefPubMed
29.
Nishiyama KK, Macdonald HM, Buie HR et al (2010) Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia than women with normal aBMD: an in vivo HR-pQCT study. J Bone Miner Res 25:882–890PubMed
30.
Pistoia W, van Rietbergen B, Lochmuller EM et al (2004) Image-based micro-finite-element modeling for improved distal radius strength diagnosis: moving from bench to bedside. J Clin Densitom 7:153–160CrossRefPubMed
31.
Macneil JA, Boyd SK (2008) Bone strength at the distal radius can be estimated from high-resolution peripheral quantitative computed tomography and the finite element method. Bone 42:1203–1213CrossRefPubMed
32.
Hansen S, Hauge EM, Beck Jensen JE, Brixen K (2013) Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT. J Bone Miner Res 28:736–745CrossRefPubMed
33.
Farmer S, Ocias LF, Vestergaard H et al (2015) Bone morbidity in chronic myeloproliferative neoplasms. Expert Rev Hematol 8:447–456CrossRefPubMed
34.
Farmer S, Hermann AP, Vestergaard H. [Severe osteoporosis in a patient with polycythaemia vera.]. Ugeskr Laeger 2014; 176.
35.
36.
van der Veer E, van der Goot W, de Monchy JG et al (2012) High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 67:431–438CrossRefPubMed
37.
Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128:344–350CrossRefPubMed
38.
Panteli KE, Hatzimichael EC, Bouranta PK et al (2005) Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 130:709–715CrossRefPubMed
39.
Rossini M, Zanotti R, Viapiana O et al (2014) Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin N Am 34:383–396CrossRef
40.
Rossini M, Zanotti R, Bonadonna P et al (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 49:880–885CrossRefPubMed
41.
Barete S, Assous N, de Gennes C et al (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69:1838–1841CrossRefPubMed
42.
Lacativa PG, Farias ML (2010) Osteoporosis and inflammation. Arq Bras Endocrinol Metabol 54:123–132CrossRefPubMed
43.
Oliveira A, Vaz C. The role of sarcopenia in the risk of osteoporotic hip fracture. Clin Rheumatol 2015.
Metadata
Title
Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera
Publication date
01-02-2017
Published in
Osteoporosis International / Issue 2/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3788-z

Other articles of this Issue 2/2017

Osteoporosis International 2/2017 Go to the issue

Review

Bone imaging in hypoparathyroidism

Original Article

Are milk and alternatives and fruit and vegetable intakes during adolescence associated with cortical and trabecular bone structure, density, and strength in adulthood?

Original Article

A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women

Letter

Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention

Original Article

Early post-surgical cognitive dysfunction is a risk factor for mortality among hip fracture hospitalized older persons

Original Article

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients